ClinicalTrials.gg
Status unknownNCT03561051Updated May 1, 2024

The Pre-hospital Evaluation of Sensitive Troponin (PRESTO) Study

An observational study in Chest Pain, Acute Coronary Syndrome and Heart Attack, sponsored by Manchester University NHS Foundation Trust. Status unknown at 13 sites in United Kingdom. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-05-01.

Sponsored by Manchester University NHS Foundation Trust · Observational

The sponsor has not verified this record recently (last verified Apr 2024), so the status shown — last known as Active, not recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
700
Ages
18 Years to 100 Years
Sex
All
01

Study summary

The aim of the study is to assess whether a decision aid that is currently used in hospitals across Greater Manchester to determine how likely it is that a patient has a serious heart problem is still accurate in the pre-hospital environment.

Read the detailed description

The Investigators will aim to recruit up to 700 participants, aged 18-100, who call 999 with a complaint of chest pain and are subsequently attended by the ambulance service. A blood sample will be taken in the ambulance as well as information about the participant's symptoms, past medical history, physical examination findings and heart tracing findings. The participant will then be transferred to hospital, where another blood sample will be taken. Both of these blood samples will be analysed at a later date for the cardiac marker, troponin.

Participants will then be followed up after 30 days via screening of their clinical records and contacting their GP. The investigators will gather information on the participant's initial admission to hospital, as well as any further hospital admissions and investigations that have occurred within the 30 days since this admission. The information collected will include data on serial cardiac marker testing; other laboratory analyses; length of stay; all imaging investigations and procedures; and details of any haemorrhagic complications.

02

Conditions studied

  • Chest Pain
  • Acute Coronary Syndrome
  • Heart Attack

Keywords

  • T-MACS
  • Pre-hospital environment
03

In context

Chest Pain

388 studies on the registry are indexed under Chest Pain; 67 are open to participants now.

This study's planned enrollment of 700 is above the median of 500 across 167 observational studies indexed under Chest Pain.

Browse Chest Pain studies →

Lead sponsor

Manchester University NHS Foundation Trust is the lead sponsor of 139 studies on the registry; 26 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study will recruit patients who have called 999 with a complaint of pain, discomfort or pressure in the chest, who are then attended by an ambulance.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (>18 years)
  • Called 999 for an emergency ambulance because they have experienced pain, discomfort or pressure in the chest, epigastrium, neck, jaw or upper limb without an apparent non-cardiac source
  • Treating paramedic suspects these symptoms may be caused by acute coronary syndromes.

Exclusion criteria

Exclusion Criteria:

  • Patients with unequivocal evidence of ST elevation myocardial infarction who are being immediately transferred for primary percutaneous coronary intervention
  • Patients in whom an alternative diagnosis (other than acute coronary syndromes) is suspected, which would necessitate transfer to hospital
  • Patients who have not experienced symptoms in the previous 24 hours
  • Patients who lack the capacity to provide written informed consent, either because they lack the mental capacity to provide written informed consent or because effective communication is not possible (e.g. non-English speakers in the absence of adequate translation services)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
700 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. Diagnosis of acute myocardial infarction

    Time frame: 30 days

Secondary outcomes

  1. Incident major adverse cardiac events

    Time frame: 30 days

  2. Prevalent acute myocardial infarction

    Time frame: 30 days

  3. Final diagnosis of participant

    Time frame: 30 days

07

Study locations

13 sites
  • Bolton NHS Foundation Trust
    Bolton, United Kingdom
  • North West Ambulance Service NHS Trust
    Bolton, United Kingdom
  • North Bristol NHS Trust
    Bristol, United Kingdom
  • University Hospitals Coventry and Warwickshire NHS Trust
    Coventry, United Kingdom
  • West Midlands Ambulance Service NHS Foundation Trust
    Dudley, United Kingdom
  • Royal Devon and Exeter NHS Foundation Trust
    Exeter, United Kingdom
  • South Western Ambulance Service NHS Foundation Trust
    Exeter, United Kingdom
  • Manchester University NHS Foundation Trust
    Manchester, United Kingdom
  • Plymouth Hospitals NHS Trust
    Plymouth, United Kingdom
  • Salford Royal NHS Foundation Trust
    Salford, United Kingdom
  • Taunton and Somerset NHS Foundation Trust
    Taunton, United Kingdom
  • South Warwickshire NHS Foundation Trust
    Warwick, United Kingdom
  • Wrightington, Wigan and Leigh NHS Foundation Trust
    Wigan, United Kingdom
08

References and documents

Publications

  • Gilman J, Alghamdi A, Hann M, Carlton E, Cooper JG, Cook E, Siriwardena AN, Phillips J, Thompson A, Bell S, Kirby K, Rosser A, Body R. Diagnostic Accuracy of a Novel Point of Care High-Sensitivity Troponin Assay in the Prehospital Environment. Acad Emerg Med. 2026 Jan;33(1):e70213. doi: 10.1111/acem.70213. PubMed 41528153 ↗
  • Alghamdi A, Hann M, Carlton E, Cooper JG, Cook E, Foulkes A, Siriwardena AN, Phillips J, Thompson A, Bell S, Kirby K, Rosser A, Body R. Diagnostic Accuracy of Clinical Pathways for Suspected Acute Myocardial Infarction in the Out-of-Hospital Environment. Ann Emerg Med. 2023 Oct;82(4):439-448. doi: 10.1016/j.annemergmed.2023.04.010. Epub 2023 Jun 10. PubMed 37306636 ↗
  • Alghamdi A, Cook E, Carlton E, Siriwardena A, Hann M, Thompson A, Foulkes A, Phillips J, Cooper J, Bell S, Kirby K, Rosser A, Body R. PRe-hospital Evaluation of Sensitive TrOponin (PRESTO) Study: multicentre prospective diagnostic accuracy study protocol. BMJ Open. 2019 Oct 28;9(10):e032834. doi: 10.1136/bmjopen-2019-032834. PubMed 31662404 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03561051
Collaborators
National Institute for Health Research, United Kingdom, Abbott Point of Care, LumiraDx, Roche Diagnostics GmbH
Responsible party
Sponsor
First posted
Jun 19, 2018
Start date
Oct 16, 2018
Primary completion
Jan 1, 2025 (estimated)
Completion
Jan 1, 2025 (estimated)
Last update
May 1, 2024

Study contacts

Richard Body
principal investigator · Manchester University NHS Foundation Trust

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion